Ignite Creation Date:
2025-12-24 @ 10:23 PM
Ignite Modification Date:
2026-02-12 @ 7:48 PM
Study NCT ID:
NCT06834035
Status:
RECRUITING
Last Update Posted:
2025-08-06
First Post:
2025-02-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Sponsor:
M. Peter Marinkovich
Organization:
Study Overview
Official Title:
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Status:
RECRUITING
Status Verified Date:
2025-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IV IgG
Brief Summary:
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum.
Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: